Phase II trial of carboplatin in patients with advanced melanoma (Q33372601)

26 July 2017

Phase II trial of carboplatin in patients with advanced melanoma (English)

1 reference

26 July 2017

phase II clinical trial

0 references

1 reference

1 reference

1 November 2022

1 reference

1 November 2022

author name string

E. S. Casper

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1696568

1 November 2022

D. Bajorin

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1696568

1 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1696568

1 November 2022

publication date

1 May 1990

1 reference

full work available at URL

26 July 2017

http://link.springer.com/content/pdf/10.1007/BF00177256.pdf

file format

Portable Document Format

1 reference

http://link.springer.com/article/10.1007/BF00177256/fulltext.html

1 November 2022

1 reference

http://link.springer.com/content/pdf/10.1007/BF00177256

1 November 2022

1 reference

Investigational New Drugs

1 November 2022

published in

1 reference

26 July 2017

8

1 reference

26 July 2017

2

1 reference

26 July 2017

187-190

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00177256

26 July 2017

0 references

cites work

Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma

1 reference

12 December 2020

Combination chemotherapy in metastatic malignant melanoma.A randomized study of three DTIC-containing combinations

1 reference

12 December 2020

Phase II trial of carboplatin in advanced malignant melanoma

1 reference

12 December 2020

WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.

1 reference

12 December 2020

DTIC (NSC-45388) in malignant melanoma: a perspective

1 reference

12 December 2020

Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites

1 reference

12 December 2020

Combination chemotherapy with dacarbazine and vindesine in the treatment of metastatic malignant melanoma

1 reference

12 December 2020

Treatment of metastatic malignant melanoma with vinblastine, dacarbazine, and cisplatin: a report from the Cancer and Leukemia Group B

1 reference

12 December 2020

Phase 1 study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion

1 reference

12 December 2020

Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study

1 reference

12 December 2020

Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma

1 reference

12 December 2020

Vinblastine, bleomycin, and cis-platinum for the treatment of metastatic malignant melanoma. National Cancer Institute of Canada Melanoma Group

1 reference

12 December 2020

Results with methyl-CCNU and DTIC in metastatic melanoma

1 reference

12 December 2020

Treatment of metastatic malignant melanoma with dacarbazine and cisplatin

1 reference

12 December 2020

Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma

1 reference

12 December 2020

cis-Dichlorodiammineplatinum(II) and DTIC in malignant melanoma

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00177256

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference